Home > Result Summaries: Compounds > fosamprenavir > Result Summary for APV10011

Result Summary for APV10011

Result Summary

Protocol ID:	APV10011
Clinical Study ID:	APV10011
Official Title:	A Phase I, Open, Randomized, Balanced, Incomplete Crossover Drug-Drug Interaction Study to Assess the Steady-State Plasma Amprenavir and Lopinavir Pharmacokinetics following Administration of Lopinavir 533mg/Ritonavir 133mg BID + GW433908 1400mg BID, GW433908 700mg BID + Ritonavir 100mg BID, or…
Phase:	Phase 1
Study Indications or Diseases:	Infection, Human Immunodeficiency Virus
Generic Name:	fosamprenavir
Trade/Product Name:	lexiva;lexiva
Approved Drug Label:	http://www.gsk.com/products.html
Results Summary:	Click here to download result summary.
Citations:	Wire MB, Naderer OJ, Masterman AL, et al. The pharmacokinetic interaction between GW433908 and lopinavir/ritonavir (APV10011and APV 10012). Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections; February 8-11, 2004; San Francisco, California. Abstract 612.